CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [1] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Robrecht, Sandra
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Illmer, Thomas
    Klaproth, Holger
    Estenfelder, Sven
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Bottcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [2] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Klaproth, Holger
    Tausch, Eugen
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2015, 126 (23)
  • [3] CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
    von Tresckow, J.
    Cramer, P.
    Bahlo, J.
    Engelke, A.
    Langerbeins, P.
    Fink, A. -M.
    Klaproth, H.
    Tausch, E.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Boettcher, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 117 - 118
  • [4] CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group
    von Tresckow, J.
    Cramer, P.
    Bahlo, J.
    Engelke, A.
    Langerbeins, P.
    Fink, A. -M
    Klaproth, H.
    Tausch, E.
    Fischer, K.
    Wendtner, C-M
    Kreuzer, K. -A
    Stilgenbauer, S.
    Boettcher, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 121 - 121
  • [5] Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
    von Tresckow, Julia
    Cramer, Paula
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Illmer, Thomas
    Klaproth, Holger
    Tausch, Eugen
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara F.
    Hallek, Michael
    LEUKEMIA, 2022, 36 (08) : 2125 - 2128
  • [6] CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
    Julia von Tresckow
    Paula Cramer
    Jasmin Bahlo
    Sandra Robrecht
    Petra Langerbeins
    Anna-Maria Fink
    Othman Al-Sawaf
    Thomas Illmer
    Holger Klaproth
    Sven Estenfelder
    Matthias Ritgen
    Kirsten Fischer
    Clemens-Martin Wendtner
    Karl-Anton Kreuzer
    Stephan Stilgenbauer
    Sebastian Böttcher
    Barbara F. Eichhorst
    Michael Hallek
    Leukemia, 2019, 33 : 1161 - 1172
  • [7] CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
    von Tresckow, Julia
    Cramer, Paula
    Bahlo, Jasmin
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Illmer, Thomas
    Klaproth, Holger
    Estenfelder, Sven
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara F.
    Hallek, Michael
    LEUKEMIA, 2019, 33 (05) : 1161 - 1172
  • [8] Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
    Julia von Tresckow
    Paula Cramer
    Sandra Robrecht
    Petra Langerbeins
    Anna-Maria Fink
    Othman Al-Sawaf
    Moritz Fürstenau
    Thomas Illmer
    Holger Klaproth
    Eugen Tausch
    Matthias Ritgen
    Kirsten Fischer
    Clemens-Martin Wendtner
    Karl-Anton Kreuzer
    Stephan Stilgenbauer
    Sebastian Böttcher
    Barbara F. Eichhorst
    Michael Hallek
    Leukemia, 2022, 36 : 2125 - 2128
  • [9] Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
    Von Tresckow, Julia
    Cramer, Paula
    De Silva, Nisha
    Bahlo, Jasmin
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Furstenau, Moritz
    Illmer, Thomas
    Klaproth, Holger
    Tausch, Eugen
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2019, 134
  • [10] Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Bahlo, Jasmin
    Robrecht, Sandra
    Al-Sawaf, Othman
    Langerbeins, Petra
    Engelke, Anja
    Fink, Anna-Maria
    Fischer, Kirsten
    Seiler, Till
    von Weikersthal, Ludwig Fischer
    Hebart, Holger
    Kreuzer, Karl-Anton
    Rittgen, Matthias
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 149 - 150
12345